CORRESPONDENCE • CID 2021:72 (15 June) • e1159 especially at its onset [9]. However, the application of a standard approach to management of patients with acute res- piratory failure and/or fever and the knowledge of clinical and laboratory characteristics of COVID-19 can drive early therapeutic choices [10]. Notes Author contributions. Conceived and designed study: A. R. and V. B. Performed data collection: A. R., V. B., L. B., F. M. C., G. C., R. P., A. S., and R. R. Analyzed data: A. R. and V. B. Wrote the man- uscript: A. R., G. C., G. D., F. P., C. M., and F. S. Potential conficts of interest. Te authors: No potential conficts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conficts of Interest.  Alessandro Russo, 1 Valeria Bellelli, 1 Giancarlo Ceccarelli, 2 Federica Marincola Cattaneo, 1 Luigi Bianchi, 1 Roberto Pierro, 1 Roberta Russo, 1 Alessia Steffanina, 1 Francesco Pugliese, 3 Claudio Maria Mastroianni, 2 Gabriella d’Ettorre, 2 and Francesco Sabetta 1 1 Internal Medicine Unit, Policlinico Casilino, Rome, Italy, 2 Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy, and 3 Department of Anesthesia and Intensive Care Medicine, Sapienza University of Rome, Rome, Italy References 1. Munblit D, Nekliudov NA, Bugaeva P, et al. StopCOVID cohort: an observational study of 3,480 patients admitted to the Sechenov University hospital network in Moscow city for suspected COVID-19 infection [manuscript published on- line ahead of print 9 October 2020]. Clin Infect Dis 2020. doi:10.1093/cid/ciaa1535. 2. Bartoletti M, Giannella M, Scudeller L, et al. Development and validation of a prediction model for severe respiratory failure in hospitalized pa- tients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study). Clin Microbiol Infect 2020; 26:1545–53. 3. Grasselli G, Zangrillo A, Zanella A, et al; COVID- 19 Lombardy ICU Network. Baseline characteris- tics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020; 323:1574–81. 4. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective co- hort study. Lancet 2020; 395:1054–62. 5. Bassetti M, Vena A, Giacobbe DR. The novel Chinese coronavirus (2019-nCoV) infections: challenges for fighting the storm. Eur J Clin Invest 2020; 50:e13209. 6. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ; HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395:1033–4. 7. Vena A, Giacobbe DR, Di Biagio A, et al. Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy. Clin Microbiol Infect 2020; 26:1537–44. 8. Paolisso P, Bergamaschi L, D’Angelo EC, et al. Preliminary experience with low molecular weight heparin strategy in COVID-19 patients. Front Pharmacol 2020; 11:1124. 9. Alhazzani W, Møller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the man- agement of critically ill adults with coronavirus disease 2019 (COVID-19). Crit Care Med 2020; 48:e440–69. 10. Sinha P, Calfee CS, Cherian S, et al. Prevalence of phenotypes of acute respiratory distress syn- drome in critically ill patients with COVID-19: a prospective observational study [manuscript published online ahead of print 27 August 2020]. Lancet Respir Med 2020. doi:10.1016 /S2213-2600(20)30366-0. Correspondence: A. Russo, Internal Medicine Unit, Policlinico Casilino, Via Casilina, 1049, Rome 00169, Italy (alessandro.russo1982@gmail.com). Clinical Infectious Diseases ® 2021;72(12):e1158–9 © The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. DOI: 10.1093/cid/ciaa1745 Reply to Russo et al To the Editor—We thank Russo and col- leagues for taking the time to critically appraise and respond to our recent ar- ticle. We assessed clinical and laboratory characteristics of patients admitted to the Sechenov University hospital net- work in Moscow, Russia, for suspected coronavirus disease 2019 (COVID-19) infection. We read about the findings of the RESILIENCY study [1] with great interest, as they are much in agreement with the results from our cohort. This further confirms the importance of ap- propriate clinical management of all ad- mitted patients with suspected severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, irrespective of the reverse-transcription polymerase chain reaction (RT-PCR) result. In their study, Russo et al [1] dem- onstrated that more than half of the ad- mitted patients did not have positive Acute respiratory failure and/or fever in Emergency Department 1° nasopharingeal swab 2° nasopharingeal swab after 24 hours Evaluation for broncoalveolar lavage for SARS- CoV-2 detection Follow-up with lung ultrasound, evaluation for transthoracic echocardiography Negative Negative Blood cultures if fever PCT value >0.5 ng/ml: empiric antibiotic therapy Including: -Routine tests -PCT -CRP -Antibodies for SARS-CoV-2 -LDH -CPK -D-Dimer -Hemogasanalysis -Lactates If excluded SARS-CoV-2 etiology transfer to non-COVID-19 section Airborne isolation CT scan Blood exams Figure 1. Management of suspected coronavirus disease 2019 at time of admission to emergency department. Abbreviations: COVID-19, coronavirus disease 2019; CPK, creatine phosphokinase; CRP, C-reactive protein; CT, computed tomography; LDH, lactate dehydrogenase; NP, nasopharyngeal; PCT, procalcitonin; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. Downloaded from https://academic.oup.com/cid/article/72/12/e1159/5989501 by guest on 11 April 2022